Bendamustine Hydrochloride 100mg Powder For Concentrate For Solution For Infusion

Product Description

Bendamustine Hydrochloride 100mg Powder For Concentrate For Solution For Infusion is a vital medication used in the treatment of certain types of cancer. This pharmaceutical product is precisely formulated to deliver effective therapeutic results as part of a comprehensive cancer care regimen. It is an alkylating agent, which works by damaging the DNA of cancer cells, thereby inhibiting their growth and division. Widely used in healthcare settings, this medication ensures high standards of quality and efficacy for patients undergoing chemotherapy.

Benefits of Use

• Effective treatment for chronic lymphocytic leukemia (CLL), a type of cancer that affects white blood cells.
• Indicated for the treatment of indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
• Acts by interfering with DNA replication and transcription in rapidly dividing cancer cells, leading to their destruction.
• Administered under strict medical supervision to maximize therapeutic benefits and manage potential side effects.

How to Use

Bendamustine Hydrochloride 100mg is administered intravenously and must be prepared and given by a qualified healthcare professional.

1. The powder is first reconstituted with sterile water for injection, following specific guidelines provided by the manufacturer.
2. The reconstituted solution is then further diluted in a suitable intravenous infusion fluid, such as 0.9% sodium chloride injection.
3. The diluted solution is administered as an intravenous infusion over a period of 30 to 60 minutes.
4. The dosage and duration of treatment cycles are determined by the treating physician based on the patient's condition, type of cancer, and response to therapy.
5. It is typically given on Day 1 and Day 2 of a 21-day or 28-day treatment cycle.

Caution & Warnings

• Bone Marrow Suppression: May cause severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Regular monitoring of blood counts is essential during treatment.
• Infections: Patients may be at increased risk of opportunistic infections, including pneumonia and herpes zoster.
• Infusion Reactions: Acute hypersensitivity or anaphylactic reactions have been reported. Monitor patients closely during and after infusion.
• Tumor Lysis Syndrome (TLS): Risk of TLS can occur, especially in patients with high tumor burden. Hydration and monitoring of blood chemistries are recommended.
• Skin Reactions: Severe skin reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, have been reported.
• Hepatotoxicity and Nephrotoxicity: Liver and kidney function should be monitored regularly.
• Embryo-Fetal Toxicity: Bendamustine can cause fetal harm. Pregnant women should be advised of the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment and for several months after.
• Breastfeeding: It is not known whether bendamustine is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, mothers should be advised not to breastfeed during treatment.
• Administration: This medication should only be administered by healthcare professionals experienced in the administration of anticancer agents.

Ingredients

• Active Ingredient: Bendamustine Hydrochloride 100mg
• Excipients: Mannitol, Hydrochloric acid (for pH adjustment)

Product Details

• Strength: 100mg per vial
• Dosage Form: Powder for concentrate for solution for infusion
• Storage: Store unopened vials at refrigerated temperatures (2°C to 8°C). Protect from light. Refer to specific manufacturer instructions for stability after reconstitution and dilution.